Runway Healthcare

Runway operates as a venture studio, not a traditional venture capital fund. It forms and wholly owns medical device companies, providing centralized management, engineering, and regulatory infrastructure. Each portfolio company is led by the same executive team — Jeff O'Donnell, Jr. as CEO and William Rhoda as technical lead — across all four platform entities.

Jeff O'Donnell, Jr. holds the CEO title across all four platform companies and appears to be the primary decision-maker. William Rhoda leads technical development as President and CTO. Jeff O'Donnell, Sr. serves as Executive Chairman across the portfolio, suggesting a family-involved governance structure. The concentrated leadership team handles deal selection, product development, and corporate strategy.

Runway does not deploy capital through a blind-pool fund. It launches and controls operating companies directly, maintaining full ownership rather than taking minority equity or LP positions. There is no evidence of fund commitments to external GPs or passive investment vehicles.

The firm focuses exclusively on orthopedics, with platform companies spanning spine surgery (Waypoint Orthopedics), foot and ankle deformity correction (Toetal Solutions), trauma and fracture care (Crossover Medical), and anatomically contoured foot and ankle trauma implants (Pace Surgical). Runway shows no current activity in digital health, cardiovascular, neurology, or surgical robotics.

Runway builds companies around surgeon-founded product ideas. Several named advisors — including specialists from Penn Medicine, Mercy Medical Center, and NYU Langone Health — provide clinical input on product design. The studio appears to originate concepts through these surgeon relationships rather than through an open-application process or third-party accelerator.

Jeff O'Donnell, Jr. (CEO), William Rhoda (CTO), and Jeff O'Donnell, Sr. (Executive Chairman) hold identical leadership roles across all four portfolio companies, indicating a tightly held, family-influenced governance structure. No other family members are named in operating roles, and the firm has not publicly addressed succession or ownership dispersion.

Runway's website describes the firm as 'A Medical Device Venture Studio' without marketing any external fund products. The absence of disclosed third-party LP structures or public fundraising suggests the entity may be privately capitalized, potentially by the O'Donnell and Rhoda principals. However, Runway has never publicly confirmed its capital source, and it does not describe itself as a family office.